Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Kamada ( (IL:KMDA) ) is now available.
On September 2, 2025, Kamada Ltd. announced its participation in two major investor conferences: the 2025 Wells Fargo Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. CEO Amir London will present and hold one-on-one meetings with investors. This participation underscores Kamada’s proactive engagement with the investment community, potentially enhancing its market visibility and attracting new investment opportunities.
The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs2713.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies. The company focuses on treating rare and serious conditions and aims to drive growth through organic commercial activities, business development, plasma collection expansion, and advancing product candidates. Kamada’s portfolio includes FDA-approved products like KEDRAB®, CYTOGAM®, and GLASSIA®, among others. It operates three plasma collection centers in Texas and is progressing with its InnovAATe clinical trial.
Average Trading Volume: 39,567
Technical Sentiment Signal: Buy
Current Market Cap: ILs1.33B
Learn more about KMDA stock on TipRanks’ Stock Analysis page.